Jan 12, 2026 7:00 am EST MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
Nov 3, 2025 7:01 am EST Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 29, 2025 10:14 pm EDT Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering